Lobby organisation
Takeda Pharmaceuticals International AG
Company · Health & pharma · HQ: Switzerland · Transparency Register entry
As of 7 November 2026, Takeda Pharmaceuticals International AG appears in 14 declared MEP meetings (11 different MEPs), most often with European People's Party.
In their own words
“Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in our distinguished 244-year history in Japan.”
Read the rest of the statementShow less of the statement
“Established by our founding spirit and integral to every part of our business, Takeda-ism and our priorities (Patient, Trust, Reputation, Business) guide us in our efforts to achieve our Vision 2025. Takeda is headquartered in Tokyo, Japan and focuses its R&D on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. We aspire to bring our leadership in translating science into life-changing medicines to the next level, in our core focus areas: oncology, gastroentero (...)”
Stated goals from the organisation's own Transparency Register filing.
Who they meet, and when
Which groups they meet
Share of this organisation's 14 declared meetings, by the meeting MEP's political group.
Meetings by year
Declared meetings per calendar year, 2023–2026. Bar length is relative to its busiest year (6 in 2023). Hatched: 2026 is a part-year - the record runs to 6 Nov 2026.
Group is each MEP's current political group, not necessarily the one they sat with at the time. Shares are rounded to whole percent.
The MEPs they meet most
The 14 most recent declared meetings
| Date | MEP | Subject |
|---|---|---|
| 10 Sep 2026 | Aurelijus Veryga | Biopharmaceutical Manufacturing and Security of Supply of Critical Medicines |
| 1 Jul 2026 | Billy Kelleher | BioTech Act |
| 29 Apr 2026 | Margarita de la Pisa Carrión | SANT COMMITTEE ONGOING WORK |
| 19 Feb 2026 | Elena Nevado del Campo | Salud pública |
| 28 Jan 2026 | Billy Kelleher | Pharmaceutical Leglslation |
| 11 Dec 2024 | Niels Flemming Hansen | Priorites for the mandate |
| 10 Dec 2024 | Christian Ehler | Industrial Policy |
| 10 Dec 2024 | Stine Bosse | European health policy |
| 13 Jul 2023 | Günther Sidl | General Exchange of Views |
| 4 Jul 2023 | Andreas Glück | Pharmaceutical legislation |
| 1 Jun 2023 | Salvatore de Meo | SoHO |
| 7 Mar 2023 | Salvatore de Meo | SoHO |
| 21 Feb 2023 | Kateřina Konečná | SOHO regulation |
| 10 Jan 2023 | Andreas Glück | SoHo |
Meeting an MEP is a normal part of democratic life; the record is shown so anyone can see it.